panfotocoagulation (PASCAL)
ApprovedSmall molecule
panfotocoagulation (PASCAL) is one of 32 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Proliferative Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Lucentis
RochePhase 3
Inderal
WWyeth-Lederle Vaccines
Approved
Decadron
AAspen Global Incorporated
Approved
Sandostatin
Sun PharmaApproved
Beovu
NovartisPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Macugen
PfizerPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Macugen Pegaptanib Sodium
EEyetech Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for panfotocoagulation (PASCAL). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Sao Paulo